Feb. 6, 2003 — Ertapenem once daily was as efficacious and well tolerated for intra-abdominal infections as piperacillin/tazobactam four times daily, according to ...

Approval of this indication is based on limited clinical safety and efficacy data for Emblaveo. In REVISIT, study participants with cIAI (n=312) were randomly assigned 2:1 to receive ...

Feb 7 (Reuters) - AbbVie (ABBV.N), opens new tab said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections, including those caused by ...

The FDA has approved aztreonam and avibactam (Emblaveo) in combination with metronidazole for adults who have limited or no alternative options for the treatment of complicated intra-abdominal ...

Please provide your email address to receive an email when new articles are posted on . Emblaveo is the first monobactam/beta-lactamase inhibitor and antibiotic combination approved for this condition ...

Doribax (doripenem injection), a 500-mg IV infusion for treating complicated UTIs (cUTI), including pyelonephritis, as well as intra-abdominal infections (cIAI), has received marketing clearance. In ...

ZERBAXA The approvals were based on data from pediatric trials evaluating treatment for complicated intra-abdominal infections and complicated urinary tract infections. The Food and Drug ...

The Surgical Infection Society (SIS) presents new evidence-based guidelines for the management of intra-abdominal infection (IAI) in the peer-reviewed journal Surgical Infections. Click here to read ...

AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in conjunction with metronidazole for people aged 18 and over with complicated ...

The Food and Drug Administration (FDA) has approved Emblaveo™ (aztreonam and avibactam), in combination with metronidazole, for patients 18 years and older who have limited or no alternative options ...